Broad-Spectrum Antimicrobial Efficacy of Cyclic Antimicrobial Peptide Against Multidrug-Resistant Staphylococcus...

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• The rise of multidrug-resistant (MDR) bacteria necessitates the development of novel antimicrobial agents.
• Antimicrobial peptides (AMPs) are a promising class of therapeutics due to their broad-spectrum activity and unique mechanisms of action.

Purpose of the Study:

• To develop and characterize a novel synthetic amphipathic helical peptide, SAP 2.8, with potent antibacterial and antibiofilm properties.
• To elucidate the mechanism of action of SAP 2.8 against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).

Main Methods:

• Synthesis and characterization of the SAP 2.8 peptide.
• Determination of minimum inhibitory concentrations (MICs) against MDR Staphylococcus aureus and MRSA clinical isolates.
• Assessment of bactericidal kinetics, cytotoxicity, and antibiofilm activity.
• Investigation of the peptide's mechanism of action, including membrane permeabilization and reactive oxygen species production.
• Evaluation of SAP 2.8 efficacy in animal models of bacterial infection.

Main Results:

• SAP 2.8 exhibited potent antibacterial activity against MDR S. aureus and MRSA, with MICs between 1.25 and 2.5 μg/mL.
• The peptide demonstrated rapid bactericidal effects within 30 minutes and low cytotoxicity to mammalian cells.
• SAP 2.8 effectively inhibited the formation of bacterial biofilms and disrupted pre-existing biofilms.
• Mechanistic studies indicated that SAP 2.8 induces bacterial membrane rupture and permeabilization, leading to increased intracellular reactive oxygen species and cell death.
• Significant reduction in bacterial load was observed in animal models treated with SAP 2.8.

Conclusions:

• SAP 2.8 is a potent synthetic antimicrobial peptide with significant antibacterial and antibiofilm activities.
• The peptide's mechanism of action involves membrane disruption and induction of oxidative stress, leading to bacterial death.
• SAP 2.8 demonstrates low mammalian cell toxicity and efficacy in vivo, representing a promising therapeutic candidate for Gram-positive bacterial infections.